Clinical and biologic implications of recurrent genomic aberrations in myeloma
Oken, Martin M.
Kyle, Robert A.
Dewald, Gordon W.
Van Ness, Brian
Van Wier, Scott A.
Henderson, Kimberly J.
Bailey, Richard J.
Greipp, Philip R.
MetadataShow full item record
Nonrandom recurrent chromosomal abnormalities are ubiquitous in multiple myeloma (MM) and include, among others, translocations of the immunoglobulin heavy chain locus (IgH). IgH translocations in MM result in the up-regulation of oncogenes, and include more commonly t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23). Based on the recurrent nature of these translocations and their finding since the early stages of the plasma cell (PC) disorders, we hypothesized that they would confer biologic and clinical variability. In addition, deletions of 13q14 and 17p13 have also been associated with a shortened survival. We used cytoplasmic Ig–enhanced interphase fluorescent in situ hybridization to detect deletions (13q14 and 17p13.1), and translocations involving IgH in 351 patients treated with conventional chemotherapy entered into the Eastern Cooperative Oncology Group clinical trial E9486/9487. Translocations were frequently unbalanced with loss of one of the derivative chromosomes. The presence of t(4; 14)(p16;q32) (n 42; 26 vs 45 months, P < .001), t(14;16)(q32;q23) (n 15; 16 vs 41 months, P .003), 17p13 (n 37; 23 vs 44 months, P .005), and 13q14 (n 176; 35 vs 51 months, P .028) were associated with shorter survival. A strati- fication of patients into 3 distinct categories allowed for prognostication: poor prognosis group (t(4;14)(p16;q32), t(14; 16)(q32;q23), and 17p13), intermediate prognosis ( 13q14), and good prognosis group (all others), with median survivals of 24.7, 42.3, and 50.5 months, respectively (P < .001). This molecular cytogenetic classification identifies patients into poor, intermediate, and good risk categories. More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations.
Is part ofBlood, 2003, vol. 101, núm. 11, p. 4569-4575
European research projects
Showing items related by title, author, creator and subject.
Falster, Daniel S.; Duursma, Remko A.; Ishihara, Masae I.; Barneche, Diego R.; FitzJohn, Richard G.; Vårhammar, Angelica; Aiba, Mashiro; Ando, Makoto; Anten, Niels P. R.; Aspinwall, Michael J.; Baltzer, Jennifer L.; Baraloto, Christopher; Battaglia, Michael; Battles, John J.; Bond-Lamberty, Ben; Breugel, Michiel van; Camac, James; Claveau, Yves; Coll Mir, Lluís; Dannoura, Masako; Delagrange, Sylvain; Domec, Jean-Christophe; Fatemi, Farrah; Feng, Wang; Gargaglione, Veronica; Goto, Yoshiaki; Hagihara, Akio; Hall, Jefferson S.; Hamilton, Steve; Harja, Degi; Hiura, Tsutom; Holdaway, Robert; Hutley, Lindsay B.; Ichie, Tomoaki; Jokela, Eric J.; Kantola, Anu; Kelly, Jeff W.; Kenzo, Tanaka; King, David; Kloeppel, Brian D.; Komiyama, Akira; Laclau, Jean-Paul; Lusk, Christopher H.; Maguire, Douglas A.; Maire, Guerric le; Mäkelä, Annikki; Markesteijn, Lars; Marshall, John; McCulloh, Katherine; Miyata, Itsuo; Mokany, Karel; Mori, Shigeta; Myster, Randall W.; Nagano, Masahiro; Naidu, Shawna L.; Nouvellon, Yann; O'Grady, Anthony P.; O'Hara, Kevin L. (Kevin Laughlin); Ohtsuka, Toshiyuki; Osada, Noriyuki; Osunkoya, Olusegun O.; Peri, Pablo L.; Petritan, Any Mary; Poorter, Lourens; Portsmuth, Angelika; Potvin, Catherine; Ransijn, Johannes; Reid, Douglas; Ribeiro, Sabina C.; Roberts, Scott D.; Rodríguez, Rolando; Saldaña-Acosta, Angela; Santa Regina Rodriguez, Ignacio; Sasa, Kaichiro; Selaya, N. Galia; Sillett, Stephen C.; Sterck, Frank; Takagi, Kentaro; Tange, Takeshi; Tanouchi, Hiroyuki; Tissue, David T.; Umehara, Toru; Utsugi, Hajime; Vadeboncoeur, Matthew A.; Valladares, Fernando; Vanninen, Petteri; Wang, Jian R.; Wenk, Elizabeth; Williams, Richard J.; Ximenes, Fabiano de Aquino; Yamaba, Atsushi; Yamada, Toshihiro; Yamakura, Takuo; Yanai, Ruth D.; York, Robert A. (Ecological Society of America, 2015)Understanding how plants are constructed i.e., how key size dimensions and the amount of mass invested in different tissues varies among individuals is essential for modeling plant growth, carbon stocks, and energy fluxes ...
Initial Immunoglobulin M ‘Flare’ after Rituximab Therapy in Patients Diagnosed with Waldenstrom Macroglobulinemia Ghobrial, Irene M.; Fonseca, Rafael; Greipp, Philip R.; Blood, Emily; Rué i Monné, Montserrat; Vesole, David H.; Gertz, Morie A. (Wiley, 2004)BACKGROUND. The goal of the current study was to characterize the initial upsurge in immunoglobulin M (IgM) levels after treatment with rituximab in patients with Waldenstrom macroglobulinemia (WM). METHODS. As part of ...
Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants Ma, Julian K-C.; Drossard, Jürgen; Lewis, David; Altmann, Friedrich; Boyle, Julia; Christou, Paul; Cole, Tom; Dale, Philip; van Dolleweerd, Craig J.; Isitt, Valerie; Katinger, Dietmar; Lobedan, Martin; Mertens, Hubert; Paul, Mathew; Rademacher, Thomas; Sack, Markus; Hundleby, Penelope A. C.; Stiegler, Gabriela; Stöger, Eva; Twyman, Richard M.; Vcelar, Brigitta; Fischer, Rainer (Wiley, 2015)Although plant biotechnology has been widely investigated for the production of clinical-grade monoclonal antibodies, no antibody products derived from transgenic plants have yet been approved by pharmaceutical regulators ...